5-HT 2 receptor mediates high-fat diet-induced hepatic steatosis and very low density lipoprotein overproduction in rats

Obes Res Clin Pract. 2018 Jan-Feb;12(Suppl 2):16-28. doi: 10.1016/j.orcp.2016.03.015. Epub 2016 Apr 28.

Abstract

Background: 5-HT has been shown to mediate abnormality of hepatic lipid metabolism through activation of mammalian target of rapamycin (mTOR). However, it is unclear whether 5-HT is directly involved in high-fat diet (HFD)-induced hepatic steatosis.

Materials and methods: Male rats were allocated into seven groups with control, either HFD feeding, 5-HT treatment, or HFD feeding and 5-HT treatment with or without sarpogrelate treatment, all of which were executed for 4 weeks. HepG2 cells were exposed to 5-HT or palmitic acid (PA) with or without rapamycin or Sar treatment.

Results: Rats fed with HFD or exposed to 5-HT led to abnormalities with activated hepatic mTOR-S6K pathway, overproduction of hepatic triglycerides and VLDL with steatosis, and hyperlipidemia, which were exacerbated by a combination of HFD and 5-HT. Sarpogrelate significantly inhibited above abnormalities induced by HFD and 5-HT, alone or in a combination. Additionally, HFD caused up-regulation of 5-HT2 receptors (5-HT2R), including 5-HT2AR and 5-HT2BR, and 5-HT synthesis in the liver, without obvious influence on other 5-HT receptors gene expression. In HepG2 cells, both PA and 5-HT induced overproduction of triglycerides and VLDL with lipid droplets, and PA up-regulated 5-HT2AR and 5-HT2BR expression and 5-HT synthesis as well. Rapamycin fully abolished PA or 5-HT-induced mTOR activation, which was more effective than sarpogrelate. However, the inhibitory effects of rapamycin on PA or 5-HT-induced overproduction of triglycerides and VLDL were less than sarpogrelate.

Conclusions: Up-regulation of hepatic 5-HT2R and 5-HT synthesis by HFD is crucial for HFD-induced overproduction of hepatic triglycerides and VLDL with hyperlipidemia.

Keywords: 5-HT 2 receptor; 5-HT synthesis; Hepatic lipid abnormality; Mammalian target of rapamycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cholesterol, VLDL / biosynthesis*
  • Cholesterol, VLDL / blood
  • Diet, High-Fat*
  • Disease Models, Animal
  • Fatty Liver / blood
  • Fatty Liver / metabolism*
  • Lipoproteins, VLDL / biosynthesis*
  • Lipoproteins, VLDL / blood
  • Liver / metabolism
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Serotonin, 5-HT2 / metabolism*
  • Up-Regulation

Substances

  • Cholesterol, VLDL
  • Lipoproteins, VLDL
  • Receptors, Serotonin, 5-HT2